ArticleBMC biotechnology2025
A novel single-vector featuring bidirectional promoters for production of bispecific antibody against rabies virus.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe World Health Organization (WHO) recommends combination therapy with two non-overlapping monoclonal antibodies (mAbs) to enhance protection in Rabies post-exposure prophylaxis (PEP). While bispecific antibodies (bsAbs) provide superior protection over monoclonal antibodies (mAbs) by simultaneously targeting two distinct epitopes, their development is hindered by complex and inefficient vector design. In this study, we aimed to develop a novel single-vector expression system to efficiently produce potent anti-rabies virus (RABV) neutralizing bsAbs.
resultsWe engineered a minimalistic peaSKYA single-vector featuring bidirectional dual-CMV promoters to enable synchronous co-expression of antibody heavy (HC) and light chains (LC) within a single construct. By eliminating redundant backbone elements, this optimized vector increased the expression-cassette ratio by 17% and improves transfection efficiency by 32% compared to dual-vector systems. The platform demonstrated 2-fold greater yields of bispecific antibodies in HEK293F transient expression, with the tetravalent DVD-Ig format antibody HHDVD showing significantly enhanced neutralization potency versus parental monoclonal antibodies in both pseudovirus-based neutralization assays (PBNA, 2193.19 IU/mg) and rapid fluorescent focus inhibition tests (RFFIT, 1679.52 IU/mg).
conclusionsWe developed peaSKYA single-vector expression system for robust production of bispecific antibodies, with candidate HHDVD exhibiting potential in Rabies PEP. This streamlined vector design approach exhibited remarkable potential in bispecific neutralizing antibody development, offering a transferable platform for other engineered bispecific antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.